Mi­rati sees more re­spons­es for KRAS drug in Keytru­da com­bo as it an­gles for an edge over Am­gen

With a fil­ing for its KRAS in­hibitor ada­gra­sib right around the cor­ner, Mi­rati is build­ing a grow­ing case against Am­gen as in­vestors watch with bat­ed breath. Promis­ing da­ta from a tiny sub­group of lung can­cer pa­tients treat­ed with an ada­gra­sib com­bo could whet in­vestors’ ap­petites just enough, but how will Am­gen re­spond?

In a short up­date in its Q3 earns, Mi­rati said a com­bi­na­tion of ada­gra­sib and Mer­ck’s Keytru­da post­ed four par­tial re­spons­es among eight pre­vi­ous­ly un­treat­ed, ad­vanced non-small cell lung can­cer pa­tients in a Phase Ib test, cast­ing new hope the biotech could seize a leg up on Am­gen in the fledg­ing KRAS in­hibitor race.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN